Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 8 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 11203749

    Factor VII polypeptides that are modified and uses thereof

    Catalyst Biosciences, Inc. · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  2. US 11192936

    Factor VIII chimeric proteins and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  3. US 11186873

    Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)

    Wellmarker Bio Co., LTD. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  4. US 11186646

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  5. US 11180562

    Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies

    CytomX Therapeutics, Inc. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  6. US 11168316

    Chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  7. US 11160850

    Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

    Takeda Pharmaceutical Company Limited · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted

  8. US 11141465

    Method of making a water-soluble polymer-factor VIII moiety conjugate

    Nektar Therapeutics · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted

  9. US 11135283

    Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids

    IMMUNE DESIGN CORP. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted

  10. US 11129908

    Gene therapy vectors for treating heart disease

    Tenaya Therapeutics, Inc. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted

  11. US 11097012

    Biodegradable vectors for efficient RNA delivery

    The Regents of the University of California · Granted Aug 24, 2021 · Expires Aug 19, 2041

    granted

  12. US 11091534

    Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted

  13. US 11083801

    Factor VIII mutation repair and tolerance induction

    The United States Government Represented by the Departrment of Veteran Affairs · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted

  14. US 11078286

    Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  15. US 11078264

    Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth

    UNIVERSITY OF CONNECTICUT · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  16. US 11077108

    Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition

    The Regents of the University of California · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  17. US 11066481

    Antibodies to coagulation factor XIa and uses thereof

    The Regents of the University of California · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  18. US 11066670

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  19. US 11058664

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted

  20. US 11060110

    Adeno-associated virus vectors for treatment of glycogen storage disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted

  21. US 11040125

    Neurotrophic factor carrier, method for producing the same, and method for regenerating a nerve using the same

    Wiregene Co., Ltd. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted

  22. US 11034740

    Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  23. US 11028444

    Survival predictor for diffuse large B cell lymphoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted

  24. US 11028161

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.